EXPLAINED: Vir biotechnology | Vintage Vibes

Vir's Monthly Hepatitis Delta Combination Made the Virus Undetectable in 79% of Patients in Phase 3 Trial

Vir Biotechnology reported that its monthly elebsiran-tobevibart combination made hepatitis D undetectable in 79% of patients after 48 weeks, though results have not undergone peer review.

Medical Daily · 20h ago

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Benzinga · Nov 4, 2022

5 Value Stocks To Watch In The Healthcare Sector

What Defines a Value Stock?

Benzinga · May 9, 2022

12 Health Care Stocks Moving In Wednesday's Intraday Session

 

Benzinga · Mar 30, 2022

35 Stocks Moving In Wednesday's Mid-Day Session

Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares jumped 82.6% to $4.71 after the company reported a year over year increase in Q4 sales results and issued Q1 sales guidance above analyst estimates.

Benzinga · Mar 30, 2022

24 Stocks Moving in Wednesday's Pre-Market Session

Gainers

Benzinga · Mar 30, 2022

Recap: Vir Biotechnology Q4 Earnings

Vir Biotechnology (NASDAQ:VIR) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · Feb 24, 2022